Genmab reports Phase I/II data for Rina-S in ovarian cancer

Genmab has reported data from Part C of the Phase I/II RAINFOL-01 trial of rinatabart sesutecan in patients with platinum-resistant ovarian cancer. The study evaluated 109 patients diagnosed with platinum-resistant ovarian cancer. The trial found a confirmed objective response rate of 45.9%, including five complete responses. Credit: Sai Thaw Kyar/Shutterstock.com. Genmab has reported data from Part C of the Phase I/II RAINFOL-01 trial of rinatabart sesutecan (Rina-S; GEN1184) in patients with platinum-resistant ovarian cancer. Rina-S is an investigational antibody-drug conjugate (ADC) comprising a human monoclonal antibody targeting folate receptor alpha (FRα), a hydrophilic protease-cleavable linker, and an exatecan topoisomerase I…

Source: Clinical Trials Arena